Make a donation

Wednesday, August 5, 2020

Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® SC (daratumumab), a new subcutaneous formulation of daratumumab.1 DARZALEX® SC is approved in four regimens across five indications in patients with multiple myeloma, most notably newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX® SC can be administered over approximately three to five minutes, significantly less time than intravenous (IV) DARZALEX®, which is administered over hours.2 DARZALEX® SC is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma. Read more here